CAR-T cells for pediatric malignancies: Past, present, future and nursing implications.

Area of Science:

• Pediatric Oncology
• Immunotherapy
• Hematologic Malignancies

Background:

• The treatment of pediatric cancers, particularly relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), has been revolutionized by the advent of chimeric antigen receptor-T (CAR-T) cell therapy.
• The success of CAR-T cell therapy in B-cell ALL has spurred investigations into its efficacy across a broader spectrum of pediatric malignancies.

Purpose of the Study:

• To review the introduction and evolution of CAR-T cell therapy in pediatric B-cell ALL.
• To explore ongoing and future clinical trials of CAR-T cell therapy in other pediatric cancers.
• To highlight the critical role of nursing in managing CAR-T cell therapy toxicities and ensuring patient safety.

Main Methods:

• Comprehensive literature review.
• Inclusion of first-hand institutional experience.
• Analysis of current and past clinical trial data.

Main Results:

• CAR-T cell therapy has significantly altered the treatment paradigm for relapsed/refractory pediatric B-cell ALL.
• Clinical trials are expanding CAR-T cell therapy applications to various other pediatric malignancies.
• Effective management of severe toxicities requires vigilant monitoring and adherence to safety protocols.

Conclusions:

• CAR-T cell therapy represents a major advancement in pediatric oncology, particularly for B-cell ALL.
• The potential of CAR-T cell therapy in other pediatric cancers warrants further investigation.
• Robust nursing education and involvement are paramount for optimizing patient outcomes and managing the complexities of CAR-T cell therapy.